Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181055 | 0.90 | CYP2C19 (0.38) | MAPTCYP2C19ALDH1A1TSHRPOLB | |
| SCHEMBL528085 | 0.83 | TSHR (0.42) | MAPTCYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL27886351 | 0.82 | DGAT1 (0.34) | MAPTDGAT1PKMKCNN4 | |
| SCHEMBL28097400 | 0.81 | TSHR (0.36) | MAPTALDH1A1TSHRTDP1PKM | |
| SCHEMBL3181065 | 0.81 | MMP8 (0.41) | ALDH1A1TSHRLMNAPKMHTT | |
| SCHEMBL27412775 | 0.79 | MAPT (0.41) | MAPTCYP2C19ALDH1A1TSHRPOLB | |
| SCHEMBL8201537 | 0.78 | MAPT (0.37) | MAPTCYP2C19ALDH1A1TSHRPOLB | |
| SCHEMBL10881164 | 0.78 | MAPK1 (0.38) | ALDH1A1TSHRDGAT1MMP1MMP9 | |
| SCHEMBL2302989 | 0.78 | CYP2C19 (0.36) | MAPTCYP2C19ALDH1A1POLBTDP1 | |
| SCHEMBL7975198 | 0.78 | MAPT (0.39) | MAPTCYP2C19ALDH1A1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065192-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | MAPT 3540/4885CYP2C19 4009/4885ALDH1A1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.